Research
Hormonal
Anti-obesity medications (GLP-1 RAs, MC4R agonists) and bariatric surgery work by improving appetite control and resetting the fat mass set point, rather than just creating a caloric deficit.
Medications like GLP-1 agonists and surgeries like gastric bypass succeed because they fix the broken biological signals in your brain that tell you when to stop eating. They improve appetite control, making it easier to maintain weight loss without constant willpower.
GoodSupportsHIGH confidence
All are effective in improving appetite control. The strongest predictors for successful and sustained weight loss to both medications and surgery include self-reported improvements in appetite control.
Why this rating
Based on clinical trial data and mechanistic reviews cited in the paper.
Source
Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease
Jonathan Q. Purnell et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15478
narrative_reviewCited 26×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a chronic disease driven by hypothalamic dysregulation of body fat mass set points, not by individual neglect of eating habits or exercise.Strong
- The hypothalamus regulates body fat mass through a defended set point, where afferent signals from gut hormones (GLP-1, CCK, ghrelin) and adipose tissue (leptin) modulate food intake and energy expenditure.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →